Stay updated on Nivolumab in Resectable Osteosarcoma Clinical Trial
Sign up to get notified when there's something new on the Nivolumab in Resectable Osteosarcoma Clinical Trial page.

Latest updates to the Nivolumab in Resectable Osteosarcoma Clinical Trial page
- Check7 days agoChange DetectedThe page shows a new revision stamp, v3.6.4, replacing the previous v3.6.3, indicating an update to the page version. This update is a metadata change and does not alter the study data or visible content.SummaryDifference0.0%

- Check14 days agoNo Change Detected
- Check21 days agoNo Change Detected
- Check29 days agoChange DetectedPage revision updated from v3.6.2 to v3.6.3, indicating a new revision of the study record. This update reflects a newer page version on ClinicalTrials.gov and may include minor corrections or enhancements without altering core study details.SummaryDifference0.0%

- Check36 days agoChange DetectedThe page revision label has been updated from v3.6.0 to v3.6.2, signaling a newer page build.SummaryDifference0.0%

- Check50 days agoChange DetectedNew help/navigation sections were added (How to Read a Study Record, Common Questions, How to Join a Study) and the Intervention/Treatment label formatting updated from Intervention / Treatment, with the revision version changing from v3.5.5 to v3.6.0; the recruitment status now shows No longer looking for participants.SummaryDifference0.4%

- Check57 days agoChange DetectedThe page footer now includes updated branding references to the Moffitt Cancer Center Clinical Trials website and related institution names, along with a 'Helpful Links Provided by' note, and the revision number was updated from v3.5.4 to v3.5.5.SummaryDifference0.2%

- Check64 days agoChange DetectedSponsor branding/navigation items linking to the Moffitt center and its trial resources were removed from the page header/footer, reducing quick access to sponsor-related resources.SummaryDifference0.1%

Stay in the know with updates to Nivolumab in Resectable Osteosarcoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Nivolumab in Resectable Osteosarcoma Clinical Trial page.